DDrare: Database of Drug Development for Rare Diseases

Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACETAZOLAMIDE; Acetate; Acetazolamide; Acetazolamide Sandoz 250; Adempas; Amiloride; Atorvastatin; CALCITONIN (SALMON); Calcitonin; Chlorothiazide; Confortid; DESMOPRESSIN ACETATE TRIHYDRATE; Desmopressin; Desmopressin acetate trihydrate; Desmopressine; Desmopressine nasal spray 10 mg/ml, flacon 60 doses; Esidrix; FLUCONAZOLE; Fluconazole; HYDROCHLOROTHIAZIDE; Hydrochloorthiazide; Hydrochlorothiazide; Hydrochlorothiazide/amiloride; INDOMETACIN; Indometacin; Indomethacin; Losec; Magnesium; Metformin; Miacalcic; Midamor; OMEPRAZOLE MAGNESIUM; Omeprazole; RIOCIGUAT; Riociguat; SILDENAFIL; SILDENAFIL CITRATE; SPIRONOLACTONE; SUB21605; Salmon; Sildenafil; Spirix; Spironolactone; Tolvaptan; Viagra

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02967653 (ClinicalTrials.gov)	July 13, 2017	15/11/2016	Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus	Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial	Lithium Use, Nephrogenic Diabetes Insipidus	Drug: Atorvastatin	Lady Davis Institute	NULL	Completed	18 Years	85 Years	All	60	Phase 2	Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02967653
(ClinicalTrials.gov)

July 13, 2017

15/11/2016

Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus

Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial

Lithium Use, Nephrogenic Diabetes Insipidus

Drug: Atorvastatin

Lady Davis Institute

NULL

Completed

18 Years

85 Years

All

Phase 2

Canada